Anti-Obesity Prescription Drugs Market

Growing demand for obesity is one of the recent trends in the global Anti-Obesity Prescription Drugs market. Moreover, this trend is further anticipated to drive the global Anti-Obesity Prescription Drugs market over the forecast period. Furthermore, growing obesity due unhealthy food and lifestyle such as intake of drugs due to stress, alcohol leads to growing demand for obesity management resulting in growth of this trend.

Anti-Obesity Prescription Drugs Market contains market size and forecasts of Anti-Obesity Prescription Drugs in global, including the following market information:

• Global Anti-Obesity Prescription Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global Anti-Obesity Prescription Drugs Market Sales, 2017-2022, 2023-2028, (K Units)
• Global top five Anti-Obesity Prescription Drugs companies in 2021 (%)
• The global Anti-Obesity Prescription Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
• The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
• Pediatric Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Anti-Obesity Prescription Drugs include F Hoffmann La Roche Ltd, Orexigen Therapeutics, Novo Nordisk A/s, Arena Pharmaceuticals, Glaxosmithkline, Vivus, Boehringer Ingelheim and Alizyme, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Anti-Obesity Prescription Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Anti-Obesity Prescription Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Anti-Obesity Prescription Drugs Market Segment Percentages, by Type, 2021 (%)

• Pediatric
• Adult

Global Anti-Obesity Prescription Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Anti-Obesity Prescription Drugs Market Segment Percentages, by Application, 2021 (%)

• Hospitals Pharmacies
• Retail Pharmacies
• E-commerce

Global Anti-Obesity Prescription Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Anti-Obesity Prescription Drugs Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Anti-Obesity Prescription Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
• Key companies Anti-Obesity Prescription Drugs revenues share in global market, 2021 (%)
• Key companies Anti-Obesity Prescription Drugs sales in global market, 2017-2022 (Estimated), (K Units)
• Key companies Anti-Obesity Prescription Drugs sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• F Hoffmann La Roche Ltd
• Orexigen Therapeutics
• Novo Nordisk A/s
• Arena Pharmaceuticals
• Glaxosmithkline
• Vivus
• Boehringer Ingelheim
• Alizyme